TYRA ▼ -34.5% - Tyra Biosciences, Inc. $TYRA TYRA - Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib Tyra Biosciences fell 34.5% today despite reporting positive Phase 2 results for dabogratinib in treating low-grade intermediate-risk non-muscle invasive bladder cancer. The sharp decline suggests investors may have viewed the efficacy or safety data as disappointing relative to expectations, or concerns about the competitive landscape or regulatory pathway for the treatment outweighed the clinical progress. 09-SEP-2026 07:01 AM ET